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Introduction
Rabies, encephalitis caused by lyssa-
viruses, was considered universally fatal until
a young, unvaccinated patient with bat
rabies survived after a new therapeutic
approach [1]. The long-term favourable
outcome of this patient suggested that
successful interventions may be possible
[2]. However, 11 patients, subsequently
treated in a similar way, have not survived
(reviewed by Wilde et al. [3]). Of six of these
patients, information is published [4–8]; the
other five are mentioned in the review [3].
We reporton a patientwithrabies dueto
Duvenhage virus from a bat in Kenya. A
very brief description of this case without
clinical details and without results of
virological and pathological investigations
was reported in Eurosurveillance [7]. This
report was included in the review of Wilde
et al. [3]. We now present this patient in
more detail and with results of virological
and pathological investigations. We re-
ceived written consent for publication of
this case report from the patient’s husband.
Case Report
A bat flew against the face of a 34-year-
old Dutch woman, a medical doctor, on a
campsite in Tsavo West National Park,
Kenya. She swept the animal away and
noticed two small superficial bleeding
wounds on the right side of the nose.
The wounds were washed with water and
soap, and cleaned with alcohol swabs. The
park wardens and the personnel at the
nearby health facility assured her that
locally rabies was only known to be carried
by dogs and cats. She was not referred for
postexposure prophylaxis.
Fourteen days after her return to The
Netherlands, 23 daysafter the incident with
the bat, she complained of malaise, dizzi-
ness, muscle aches, and headache. She had
no fever. Two days later, she experienced
difficulty with speech and swallowing.
There was hypaesthesia of both cheeks
and she felt unsteady. She vomited once.
She was admitted in isolation the next day,
day 4 of complaints. Her past medical
history was unremarkable and she did not
take medication.
On examination she was anxious, but
alert and well oriented. Her temperature
and other vital parameters were normal.
There was no hypersalivation, hydrophobia,
or aerophobia, and no difficulty swallowing.
The wounds on the nose were resolved;
there was no itch or pain. There was a slight
dysarthria and she spoke in a staccato way.
Apart from the hypaesthesia of both cheeks,
further neurological examination was unre-
markable. The deep tendon reflexes were
normal. On advice of the National Coordi-
nation Center for Infectious Diseases
(NCCID), she received human anti-rabies
immunoglobulin (HRIG), 20 IU/kg im,
divided over both quadriceps muscles, and
human diploid rabies vaccine (Me ´rieux) im
( d a y s1 ,4 ,8 ,a n d1 5o fa d m i s s i o n ) .O t h e r
infections, such as Rift Valley fever, West
Nile fever, lymphocytic choriomeningitis,
yellow fever, enterovirus 71 and Listeria
monocytogenes infection, malaria, and trypano-
somiasis were considered and ruled out by
appropriate tests (immunofluorescence or
enzyme-linked immunosorbent assay, cul-
ture of blood and cerebrospinal fluid (CSF)
and microscopy of blood slides and CSF,
PCR for enterovirus, inclusive of enterovirus
71). Neurological considerations included
infection by neurotropic viruses, acute
disseminated encephalomyelitis, and, initial-
ly, anxiety disorder. On day 2 of admission,
her temperature was 38.5uC, the dysarthria
had worsened, and she complained of
difficulty with swallowing. She was agitated
and she had a high frequency postural
tremor of her hands.
Serum, CSF, and a nuchal biopsy were
sent to the rabies reference laboratory,
Department of Virology, Erasmus Medical
Centre, Rotterdam. The CSF showed 12
white blood cells (lymphocytes)/3 mm
3
(n,5), no red blood cells, a protein level of
0.23 g/l (n,0.5) and a glucose level of
3.0 mmol/l (blood glucose 4.9 mmol/l).
During the following days her dysarthria
increased. She complained of weakness of
arms and legs and double vision. She
developed hypersalivation and became hy-
perreactive to noises. Her temperature was
variable with bouts of fever, up to 39.2uC.
On day 6 of admission, the condition acutely
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aspirated, and oxygenation dropped due to
respiratory insufficiency. She was intubated
a n da d m i t t e dt ot h eI n t e n s i v eC a r eU n i t
(ICU). The CSF now showed 64 white
blood cells (no differential count performed)
and 25 red blood cells/3 mm
3,ap r o t e i n
level of 0.72 g/l, and an elevated IgM index
of 0.35. An MRI showed an area of
increased signal intensity on T2-weighted
images in the posterior part of the medulla
oblongata and pons (Figure1). The next day
she was drowsy and there was nuchal
rigidity. She opened her eyes in response
to voicesand she squeezed with her left hand
and moved her legs on command. She had
horizontal and downward gaze palsies. The
deep tendon reflexes of the arms were
absent, while the leg reflexes were normal.
Rabies seemed the probable cause of the
encephalitis, but the pharyngo-cervical-bra-
chial variant of Guillain-Barre ´s y n d r o m e
(GBS) was also considered. No rabies-specific
antibodies had been detected in serum
collected before vaccination or in serum or
CSF from day 2 of admission, and Lyssavirus-
specific RT-PCR was negative in those
specimens. The nuchal biopsy, obtained on
day 2 of admission, showed a weak band of
correct size on agarose gel in nested RT-
PCR in only one of the quadruplicate
samples and therefore required confirmation
by cloning and sequencing [9] (Box 1).
Treatment with intravenous immunoglobu-
lin 0.4 g/kg/d for 5 days as for GBS and
with acyclovir 10 mg/kg three times per day
iv for 5 days as for herpes simplex enceph-
alitis was started (PCR for herpes simplex
virus and varicella zoster virus in serum and
CSF proved negative). Before rabies was
confirmed, the treatment protocol used for
the rabies patient who survived [1] was
started on day 7 of admission, after informa-
tion was provided to her husband and family
and with their consent. Treatment consisted
of induction of coma with pentobarbital
4 mg/kg/h, midazolam 5 mg/h, and keta-
mine 100 mg/h; the EEG was continuously
monitored and pentobarbital and midazo-
lam were titrated to burst suppression,
meaning to a maximum of four bursts per
minute. Administration of the antiviral
amantadine 100 mg twice per day per
nasogastric tube was started the next day
(day 8 of admission) and ribavirin iv, 1 g
four times per day, was added from day 12
onwards. Tetrahydrobiopterin and co-
enzyme Q10 were given from day 15. A
complicating pneumonia was treated with
cefotaxim 1 g iv, four times per day for 5
days. Routine ICU procedures of prophy-
lactic administration of low molecular weight
heparin, regulation of blood glucose level by
continuous administration of glucose 5%
and insulin, and selective decontamination of
digestive tract (SDD) [10] were applied.
SDD consistsofa fourtimesdailyapplication
to the buccal cavity of 0.5 g of an oral paste
containing 2% polymyxin E, 2% tobramy-
cin, and 2% amphotericin B, and once daily
administration of 100 mg polymyxin E,
80 mg tobramycin, and 500 mg amphoter-
icin B through a nasogastric tube.
On day 11 of admission the presence of
Duvenhage virus in the nuchal skin biopsy
specimen from the 2nd day of admission
was confirmed. This may seem like a long
delay, but only one of the two agarose gels
tested by PCR showed a faint band, and
the repeated test in duplicate was negative
in both tests. The amplicon had to be
cloned as direct sequencing was not
successful. Details of virological investiga-
tions are presented in Box 1.
Blood pressure, heart rhythm, kidney
function, and diuresis were regulated
by fluids and low dose noradrenaline; a
Figure 1. MRI brain on day 6 of admission. Axial T2-weighted images in a patient with rabies due to Duvenhage virus infection, at day 6 after
admission; hyperintense signal in the posterior part of the medulla oblongata (arrow).
doi:10.1371/journal.pntd.0000428.g001
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coccus aureus was treated with flucloxacillin
iv, 1 g, four times per day for 7 days. On
admission to the ICU, the temperature
was elevated up to 40.1uC, but after
administration of acetaminophen suppos-
itories (1,000 mg, four times per day, in
total given for 3 days) the temperature was
normal 24 hours later and remained
normal thereafter without further mea-
sures. Diabetes insipidus, first apparent on
day 12 of admission, day 7 of ICU, was
regulated with iv fluids to which desmo-
pressin was added on days 13, 16, and 17.
Pentobarbital was stopped after 5 days
when no bursts were seen on the EEG and
midazolam was stopped after 7 days of
administration. Twenty-four hours later, 3
days after stopping pentobarbital and
while there was no pentobarbital detect-
able in the serum, the EEG showed a very
low voltage background pattern.
MRI abnormalities of the medulla ob-
longata had increased and now extended to
mesencephalon and both dentate nuclei in
the cerebellum (Figure 2). Also, there was
diffuse swelling of both hemispheres. Mag-
netic resonance angiography did not reveal
vascular abnormalities. There was no
response to pain or acoustic stimuli after
withdrawal of ketamine. Brainstem reflexes
and deep tendon reflexes were absent.
Introduction of a tube to clean the airways
did not result in a response of coughing and
there was no spontaneous respiration. In
agreement with the wishes of the family it
was decided to stop ventilatory support.
She died on day 20 of admission, 45 days
after the incident with the bat.
At postmortem examination no gross
abnormalities were found, apart from the
pneumonia. The brain was swollen and
weighed 1,360 g. Histopathology of the
cerebral cortex (Figure 3A and 3B) showed
extensive neuropil vacuolization, neuronal
cell loss, astrogliosis, and widespread in-
flammatory changes consisting of macro-
phages, activated microglia, and lympho-
cytic infiltrates. Severe neuronal cell loss
was observed in the hippocampus, mid-
brain, pons, medulla oblongata, and cere-
Figure 2. MRI brain on day 16 of admission (4 days before death). Axial T-2 weighted images in a patient with rabies due to Duvenhage virus
infection, at day 17 after admission show increased signal in the posterior part of the medulla oblongata (arrow) and in the basal ganglia (arrows).
doi:10.1371/journal.pntd.0000428.g002
Box 1. Virological Investigations of a Patient with Duvenhage
Virus Infection
Clinical samples
Serum, d2 antibody and PCR neg, d7 antibody neg;
CSF, d2 antibody and PCR neg, d 6 and d 28 Lyssa PCR neg;
Nuchal skin biopsy, d2 PCR pos, see text, IF rabies neg, d10 PCR neg (repeated
because of delay with first biopsy);
Saliva, d7 Lyssa PCR pos (reported d 13), d10 neg;
Cornea smear, d7 IF neg.
(Note: results of tests performed.)
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clonal rabbit anti-rabies nucleoprotein
antibody showed rabies virus antigen in
the frontal and temporal cortex, as well as
in the hippocampus and entorhinal cortex
(Figure 3C and 3D). Rabies virus antigen
was not detected in other regions of the
brain nor in adrenal glands, salivary gland,
pancreas, thyroid, heart, or gastrointestinal
tract.
Materials and Methods
Antibody Detection
The Platelia Rabies II Kit (Bio-Rad,
Marnes-La-Coquette, France) was used to
detect and titrate IgG anti-rabies virus
Figure 3. Histopathology rabies encephalitis due to Duvenhage virus. Rabies encephalitis (lyssavirus; genotype 4) brain pathology: cerebral
cortex and anti-RNP Immunohistochemistry. (A) (HE staining): frontal cortex: extensive neuropil vacuolization and neuronal cell loss. (B) Few residual
cortical neurons (arrows). (C) (HE staining): perivascular lymphocytic inflammatory infiltrates (arrows). (D and E) Anti-RNP immunoreactivity within the
frontal cortex. Several neuronal cells show immunopositivity (arrows and insert in [E]) with multiple antigenic masses present in the neuronal
cytoplasm, as well as in dendrites and axon. Scale bar: (A, B) 100 mm; (C, D) 60 mm; (E) 40 mm; insert in (E): 12 mm.
doi:10.1371/journal.pntd.0000428.g003
Figure 4. Immunofluorescence tests with antirabies nucleocapside conjugate. Immunofluorescence of murine neuroblastoma cells using
antirabies nucleocapside conjugate (Bio-Rad). The arrow points to cells with positive green immunofluorescence. The right picture is a magnification
of the left with the scale bar.
doi:10.1371/journal.pntd.0000428.g004
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was also used to detect specific antibody in
CSF.
Antigen Detection Using
Immunofluorescence
Lyssavirus antigen was detected by the
immunofluorescence examination using Bio-
Rad Rabies Anti-nucleocapsid Conjugate
(Bio-Rad,Marnes-La-Coquette,France).Nu-
chal skin biopsies and corneal smears were
examined by the immunofluorescence assay
to detect the presence of rabies virus antigen.
Cell Culture
Cell culture of the various clinical
samples was carried out by inoculation of
murine neuroblastoma cells and BHK-21
cells propagated in 24-well microtiter
plates. CSF was tested without processing,
and saliva was made up to a volume of
2 mL with virus transport medium. The
other specimens were ground with virus
transport medium up to a volume of 5 mL.
After centrifugation a volume of 200 mL
was added to each well. Immunofluores-
cence tests with anti-rabies nucleocapside
conjugate (Bio-Rad) showed immunoposi-
tivity as presented in Figure 4.
Heminested PCR and Sequence
Analysis
A rabies-specific diagnostic RT-PCR
was performed as previously described
[9]. In short, nucleic acid was extracted
using the MAgNA Pure LC (Roche
Diagnostics, Penzberg, Germany) with
the Total Nucleic Acid Isolation kit.
Nested RT-PCR with primers from the
nucleoprotein encoding region was carried
out with read-out on agarose gel. Positive
bands were isolated from the agarose gel
using the Qiagen Quick Gel Extraction
Kit (Qiagen, Hilden, Germany) according
to the manufacturer’s instructions. From
the gel, extracted RT-PCR amplicons
were sequenced with the ABI BigDye
Terminator version 3.1 Cycle Sequencing
Kit (Applied Biosystems, Nieuwerkerk a/d
IJssel, The Netherlands) on an ABI 3100.
Sequences were generated with the Laser-
gene version 7 software package (DNAS-
TAR, Madison, United States) and blasted
at the NCBI database using a blastn
algorithm in the nr database.
A 367–base pair fragment in the
nucleoprotein region was sequenced and
phylogenetic analysis was performed using
Mega 3.1 (neighbour joining, Kimura 2–
parameter, 1,000 bootstrap values) [11]
(Figure 5).
It should be noted that a Duvenhage
strain had not been present in our labo-
ratory.
Figure 5. Lyssa virus phylogenetic tree with presented rabies case embedded. Phylogenetic tree of the presented rabies case (sequence
arrowed) and representative Lyssavirus genomes. Mega 3.1 tree (neighbour joining, Kimura 2–parameter, 1,000 bootstrap values) based on a 367–
base pair fragment in the nucleoprotein region. Bootstrap percentages higher than 75% are indicated. Genotype 1 = rabies virus (RV); Genotype 2 =
Lagos bat virus (LBV); Genotype 3 = Mokola virus (MV); Genotype 4 = Duvenhage virus (DV); Genotype 5 = European bat lyssavirus (EBLV) 1a and
1b; Genotype 6 = European bat lyssavirus (EBVL) 2a and 2b; Genotype 7 = Australian bat lyssavirus (ABLV). Present virus isolate in Genotype 4: DV
E2007011420 (arrowed).
doi:10.1371/journal.pntd.0000428.g005
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Newborn NIH outbred mice (RIVM,
Bilthoven, The Netherlands) were inocu-
lated intracerebrally with the various
clinical samples (submaxillary salivary
gland, tectum, cerebellum, and hippocam-
pus). The preparation of the specimens
was the same as for the cell culture. The
specimens were homogenized and a vol-
ume of 15 mL was introduced into the
central part of the upper parietal area of
the calvaria. The inoculated mice were
observed daily for a maximum of 28 days;
the inoculated mice did not show symp-
toms of infection. Rabies virus antigen
could not be detected by immunofluores-
cence of the mouse brains; furthermore,
the brains were also negative by PCR.
Further Serological Assays
Antibodies against lymphocytic chorio-
meningitis virus, Rift Valley virus, West
Nile virus, and yellow fever virus were
determined by immunofluorescence assays
or enzyme-linked immunosorbent assays.
Tissue Preparation
Tissue was fixed in 10% buffered
formalin and embedded in paraffin. Paraf-
fin-embedded tissue was sectioned at 6 mm,
mounted on organosilane-coated slides
(Sigma-Aldrich, St. Louis, Missouri, United
States), and used for hematoxylin and eosin
(H&E) staining. Apart from H&E staining,
representative sections of all brain speci-
mens were processed for conventional
histochemical staining (Bielschowsky,
Palmgren silver stain, Klu ¨ver-Barrera, and
Nissl) and immunohistochemistry.
Immunohistochemistry
Several blocks of different brain regions
(frontal-, temporal-, occipital-, motor-cor-
tex; hippocampus, entorhinal cortex; mes-
encephalon, pons, medulla oblongata, cer-
vical cord, and cerebellum) were used for
immunohistochemical analysis with neuro-
nal nuclear protein (NeuN; mouse clone
MAB377; Chemicon, Temecula, Califor-
nia, United States; 1:2000).
For the detection of the virus, polyclonal
rabbit anti-rabies-nucleoprotein antibody
(RNP; 1:500, Centre of Expertise for
Rabies, Ottawa, Canada) was used. The
immunostaining with this anti-rabies anti-
body was also performed on material from
adrenal gland, salivary gland, pancreas,
thyroid, heart, and gastrointestinal tract.
Immunohistochemistry was carried out
as previously described [12]. Briefly, paraf-
fin-embedded sections were deparaffinized,
re-hydrated, and incubated for 20 min in
0.3% H2O2 diluted in methanol. Antigen
retrieval was performed by incubation for
10 min at 121uC in citrate buffer (0.01 M,
pH 6.0)orfor the anti-RNPwith proteinase
K pretreatment (5 mg/ml for 5 minutes at
20uC; Boehringer Mannheim, Mannheim,
Germany). After incubation with the pri-
mary antibodies overnight at 4uC, ready-
for-use Powervision peroxidase system (Im-
munologic, Duiven, The Netherlands) and
3,39-diaminobenzidine (DAB; Sigma; Im-
munologic) or 3-amino-9-ethyl carbazole
(AEC, Sigma) were used to visualize the
antibodies. Sections were counterstained
with haematoxylin. Sections incubated
without the primary antibody were essen-
tially blank.
Discussion
Rabies occurs on all continents apart
from Antarctica. The causative viruses
belong to the family Rhabdoviridae, genus
Lyssavirus [13]. The genus includes rabies
virus, European bat lyssavirus 1 and 2,
Australian bat lyssavirus, Lagos bat virus,
Mokola virus, and Duvenhage virus. The
latter three together with rabies virus are
found in Africa. Four more lyssaviruses
have been isolated from bats (see [14,15]).
It is estimated that 55,000 persons die of
rabies each year, 31,000 in Asia and
24,000 in Africa [16]. In the vast majority
of cases, human infection is due to the bite
of an infected mammal, mostly dogs. The
bite, especially of bats, may be unnoticed
[17,18]. Airborne transmission is possible
but extremely rare [19]. Transmission via
transplantation of cornea, organs, and a
vascular segment from donors with unrec-
ognized rabies has occurred [20,21]. Apart
from these transplant cases, no laboratory-
confirmed human-to-human rabies trans-
mission has been documented [22]. Two
Ethiopian cases of human-to-human trans-
mission by salivary contact, notably a bite
and kissing, have been suggested, but both
lack laboratory confirmation of the cause
of death [23].
Diagnosis of rabies depends on demon-
stration of the virus or antibodies to the
virus in various specimens (serum, saliva,
CSF, a skin biopsy with hair follicles taken
from the neck, cornea impression smear,
and brain biopsy). Several methods are
available: RT-PCR, immunofluorescence
test, virus neutralization test, and virus
isolation in cell culture or animals. In the
early stages of disease, results may be
negative and tests may have to be
performed several times. Once neurolog-
ical symptoms occur, death is (almost)
universally inevitable. Only one patient,
who had not received pre- or postexposure
prophylaxis, has survived [1]. This 15-
year-old patient was diagnosed with en-
cephalitis. She did not receive rabies
immunoglobulin or rabies vaccine. Serum
and CSF from day 6 after the start of
symptoms contained antibodies to rabies
virus but virus was not isolated, viral
antigen could not be detected, and at-
tempts to amplify viral nucleic acid were
unsuccessful. She was treated with induc-
tion of coma with benzodiazepines and
barbiturates, ketamine, a substance that
had shown specific activity against rabies
in animal models [24], and with the
antiviral drugs ribavirin and amantadine.
Twenty-seven months after the bat expo-
sure there were sequelae of dysarthria and
gait difficulties, but she had graduated
from high school [2]. It was suggested that
infection by an attenuated variant bat
rabies virus or early presence of rabies
antibodies in serum and CSF could have
contributed to the success [1,25,26].
We applied the same methods of coma
induction with benzodiazepine and phe-
nobarbital with continuous monitoring of
bursts on the EEG and administered
ketamine, ribavirin, and amantadine as
reported by Willoughby et al. [1]. Unlike
the surviving patient [1], our patient was
given rabies vaccine and HRIG on
admission on the advice of the NCCID,
as at admission the diagnosis of rabies was
not evident, though possible, and a
differential diagnosis had to be considered.
It has been suggested, but it is not
definitely proved, that administration of
vaccine and immunoglobulin may be
harmful once clinical manifestations of
rabies have appeared [26]. Of the 11
patients with rabies who were treated with
coma induction, ketamine, and antiviral
drugs and who did not survive [3], three
were not given vaccine or immunoglobulin
[4,5], two received both vaccine and
HRIG [6,7], and one HRIG only and no
vaccine [8]; of five mentioned by Wilde et
al. [3] no details could be found. In 2003,
experts advised that rabies vaccine, im-
munoglobulin, ribavirin, interferon alpha,
and ketamine, preferably in combinations,
be considered for the management of
rabies [27], advice that was not refuted
in later publications [25,28]. Recently, a
Brazilian survivor of rabies was reported
on ProMED-mail ([29]; see also [30] for
questions and answers). This patient differs
from our and other non-surviving patients
in several aspects. This 15-year-old boy
was attacked by a bat. He received four
doses of rabies vaccine without immuno-
globulin before becoming symptomatic.
The first dose was given 4 days after the
bat bite. Neutralizing antibodies were
present in serum and CSF, probably early
www.plosntds.org 6 July 2009 | Volume 3 | Issue 7 | e428in the disease, but the exact timing is not
given. Virus RNA was not detected in
CSF. He was treated with midazolam,
ketamine, and amantadine and survived.
As mentioned, this patient differs from the
non-surviving patients because of the early
administration of vaccine and presence of
antibodies. Details and follow-up results
are awaited.
Rabies remains a virtually always fatal
disease. In a patient with symptomatic
rabies with neutralizing antibodies in the
CSF early in the disease, an attempt at
intensive treatment inclusive of respiratory
and cardiovascular support may be suc-
cessful. Otherwise, as there are no new
data from in vitro and animal studies and
no advice from experts on combination
treatments, the best possible medical and
nursing care with relief of symptoms and
comfort care of the patient and support of
the family is probably what can be offered
at present [3]. Studies of treatment in
animal models are urgently needed.
This is the third human case of rabies
due to Duvenhage virus infection. This
virus was for the first time isolated in 1970
from a human patient in South Africa
[31]. Paweska et al. reported on the
second South African patient in 2006
and referred to literature on isolations of
the virus from bats in South Africa and
Zimbabwe [32]. It was not known to be
present in Kenya, where rabies is known
to occur in dogs and a variety of animals
[33–35], but until recently not in bats.
Results of the first bat survey for lyssa-
viruses in Kenya, performed in 2006 and
2007, were published in 2008; Lagos bat
lyssavirus was found [36]. The camp
wardens and health personnel in the area
where our patient was infected were not
aware of the risk of bat rabies.
This tragic incident is another reminder
that even after a minor animal-related
injury the wound should be washed
thoroughly and postexposure prophylaxis
should be given. Where limited access to
postexposure prophylaxis may be expect-
ed, pre-exposure prophylaxis by vaccina-
tion is advised for travellers, especially
when travelling with children for longer
periods. Human diploid cell vaccine pro-
tects against classic rabies virus strains and
Duvenhage virus, but not Mokola virus
and Lagos bat virus; Duvenhage virus is
neutralized by RIG, but Mokola and
Lagos bat viruses are not [37,38].
Acknowledgments
We thank the National Coordination Center for
Infectious Diseases for their quick advice and
response. Mary J. Warrell, David A. Warrell,
David R. Shlim, Tom Solomon, Rodney E.
Willoughby, and Louis Nel are thanked for
advice and support.
References
1. Willoughby RE Jr, Tieves KS, Hoffman GM,
Ghanayem NS, Amlie-Lefond CM, et al. (2005)
Survival after treatment of rabies with induction
of coma. N Engl J Med 352: 2508–2514.
Available: http://content.nejm.org/cgi/reprint/
352/24/2508.pdf. Accessed 4 June 2009.
2. Hu WT, Willoughby RE Jr, Dhonau H, Mack KJ
(2007) Long-term follow-up after treatment of
rabies by induction of coma. N Engl J Med 357:
945–946. Available: http://content.nejm.org/cgi/
reprint/357/9/945.pdf. Accessed 4 June 2009.
3. Wilde H, Hemachudha T, Jackson AC (2008)
Viewpoint: management of human rabies. Re-
view. Trans R Soc Trop Med Hyg 102: 979–982.
4. HemachudhaT,SunsaneewitayakulB,DesudchitT,
Suankratay C, Sittipunt C, et al. (2006) Failure of
therapeutic coma and ketamine for therapy of
human rabies. J Neurovirol 12: 407–409.
5. US Centers for Disease Control and Prevention
(2007) Human rabies—Indiana and California,
2006. MMWR Morb Mortal Wkly Rep 56:
361–365. Available: http://www.cdc.gov/mmwr/
preview/mmwrhtml/mm5615a1.htm. Accessed 4
June 2009.
6. SchmiedelS,PanningM,LohseA,KreymannKG,
Gerloff G, et al. (2007) Case report on fatal human
rabies infection in Hamburg, Germany, March
2007. Euro Surveill 12: Eo70531.5. Available:
http://www.eurosurveillance.org/ViewArticle.
aspx?ArticleId=3210. Accessed 4 June 2009.
7. van Thiel PP, van den Hoek JA, Eftimov F,
Tepaske R, Zaaijer HJ, et al. (2008) Fatal case of
human rabies (Duvenhage virus) from a bat in
Kenya: the Netherlands, December 2007. Euro
Surveill 13(2): pii: 8007. Available: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId
=8007. Accessed 4 June 2009.
8. McDermid RC, Saxinger L, Lee B, Johnstone J,
Noel Gibney RT, et al. (2008) Human rabies
encephalitis following bat exposure: failure of
therapeutic coma. CMAJ 178: 557–561. Available:
http://www.cmaj.ca/cgi/content/full/178/5/557.
Accessed 4 June 2009.
9. Heaton PR, Johnstone P, McElhinney LM,
Cowley R, O’Sullivan E, et al. (1997) Heminested
PCR assay for detection of six genotypes of rabies
and rabies-related viruses. J Clin Microbiol 35:
2762–6. Available: http://www.pubmedcentral.nih.
gov/articlerender.fcgi?tool=pubmed&pubmedid
=9350729. Accessed 4 June 2009.
10. de Jonge E, Schultz MJ, Spanjaard L,
Bossuyt PMM, Vroom MB, et al. (2003) Effects
of selective decontamination of digestive tract on
mortality and acquisition of resistant bacteria in
intensive care: a randomised controlled trial.
Lancet 362: 1011–1006.
11. Delmas O, Holmes EC, Talbi C, Larrous F,
Dacheux L, et al. (2008) Genomic diversity and
evolution of the Lyssaviruses. PLoS ONE 3:
e2057. doi:10.1371/journal.pone.0002057. Avail-
able: http://www.plosone.org/article/info%
3Adoi%2F10.1371%2Fjournal.pone.0002057.
Accessed 4 June 2009.
12. AronicaE,GorterJA,JansenGH,vanVeelenCW,
van Rijen PC, et al. (2003) Expression and cell
distribution of group I and group II metabotropic
glutamate receptor subtypes in Taylor-type focal
cortical dysplasia. Epilepsia 4: 785–795. Available:
http://www3.interscience.wiley.com/journal/
118867299/abstract. Accessed 4 June 2009.
13. Warrell MJ, Warrell DA (2004) Rabies and other
lyssavirus diseases. Lancet 363: 959–969.
14. Hemachudha T, Wacharapluesadee S,
Laothamatas J, Wilde H (2006) Rabies. Curr
Neurol Neurosci Rep 6: 460–468.
15. Markotter W, Van Eeden C, Kuzmin IV,
Rupprecht CE, Paweska JT, et al. (2008)
Epidemiology and pathogenicity of African bat
lyssaviruses. Dev Biol (Basel) 131: 317–325.
16. Knobel DL, Cleaveland S, Coleman PG,
Fe `vre EM, Meltzer MI, et al. (2005) Re-
evaluating the burden of rabies in Africa and
Asia. Bull World Health Organ 83: 360–368.
Available: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?tool=pubmed&pubmedid
=15976877. Accessed 4 June 2009.
17. Rupprecht CE, Hanlon CA, Hemachudha T
(2002) Rabies re-examined. Lancet Infect Dis 2:
327–343.
18. De Serres G, Dallaire F, Co ˆteM, Skowronski DM
(2008) Bat rabies in the United States and Canada
from 1950 through 2007: human cases with and
without bat contact. Clin Infect Dis 46: 1329–1337.
Available: http://www.journals.uchicago.edu/doi/
pdf/10.1086/586745. Accessed 4 June 2009.
19. Davis AD, Rudd RJ, Bowen RA (2007) Effects of
aerosolized rabies virus exposure on bats and
mice. J Infect Dis 195: 1144–1150. Available:
http://www.journals.uchicago.edu/doi/pdf/10.
1086/512616. Accessed 4 June 2009.
20. Srinivasan A, Burton EC, Kuehnert MJ,
Rupprecht CE, Sutker WL, et al. (2005) Trans-
mission of rabies virus from an organ donor to
four transplant recipients. N Engl J Med 352:
1103–1111. Available: http://content.nejm.org/
cgi/reprint/352/11/1103.pdf. Accessed 4 June
2009.
2 1 .B r o n n e r tJ ,W i l d eH ,T e p s u m e t h a n o nV ,
Lumlertdacha B, Hemachudha T (2007) Organ
transplantations and rabies transmission. J Travel
Med 14: 177–180. Available: http://www3.
interscience.wiley.com/journal/118489712/
abstract. Accessed 4 June 2009.
22. Helmick CG, Tauxe RV, Vernon AA (1987) Is
there a risk to contacts of patients with rabies?
Rev Infect Dis 9: 511–518. Available: http://
www.jstor.org/stable/4454126. Accessed 4 June
2009.
23. Fekadu M, Endeshaw T, Alemu W, Bogale Y,
Teshager T, Olson JG (1996) Possible human-to-
human transmission of rabies in Ethiopia. Ethiop
Med J 34: 123–127.
24. Lockhart BP, Tordo N, Tsiang H (1992) Inhibition
of rabies virus transcription in rat cortical neurons
with the dissociative anesthetic ketamine. Antimi-
crob Agents Chemother 36: 1750–1755. Available:
http://www.pubmedcentral.nih.gov/picrender.
fcgi?artid=192041&blobtype=pdf. Accessed 4 June
2009.
25. Jackson AC (2005) Recovery from rabies [edito-
rial]. N Engl J Med 352: 2549–2550.
26. Hemachudha T, Wilde H (2005) Survival after
treatment of rabies. N Engl J Med 353:
1068–1069.
2 7 .J a c k s o nA C ,W a r r e l lM J ,R u p p r e c h tC E ,
Ertl HCJ, Dietzschold B, et al. (2003) Manage-
ment of rabies in humans. Clin Infect Dis 36:
60–63. Available: http://www.journals.uchicago.
edu/doi/pdf/10.1086/344905. Accessed 4 June
2009.
28. Jackson AC (2006) Rabies: new insights into
pathogenesis and treatment. Curr Opin Neurol
19: 267–270.
29. ProMED-mail (14 November 2008) Rabies,
human survival, bat - Brazil: (Pernambuco).
Archive number 20081114.3599. Available:
http://www.promedmail.org. Accessed 7 July
2009.
30. ProMED-mail (22 November 2008) Rabies,
human survival, bat - Brazil (02): (Pernambuco).
www.plosntds.org 7 July 2009 | Volume 3 | Issue 7 | e428Archive number 20081122.3689. Available:
http://www.promedmail.org. Accessed 7 July
2009.
31. Meredith CD, Prossouw AP, Koch HP (1971) An
unusual case of human rabies thought to be of
Chiropteran origin. S Afr Med J 45: 767–769.
32. Paweska JT, Blumberg LH, Liebenberg C,
Hewlett RH, Grobbelaar AA, et al. (2006) Fatal
human infection with rabies-related Duvenhage
virus, South Africa. Emerg Infect Dis 12: 1965–1967.
Available: http://www.cdc.gov/ncidod/eid/
vol12no12/06-0764.htm. Accessed 4 June 2009.
33. Department of Veterinary Services (1974) Rabies.
I n :V o g e lL C ,M u l l e rA S ,O d i n g oR S ,
Onyango Z, de Geus A, eds. Health and disease
in Kenya. Nairobi: East African Literature
Bureau. pp 297–299.
34. Kariuki DP, Ngulo WK (1985) Epidemiology of
animal rabies in Kenya. In: Kuwert E, Me ´rieux C,
Koprowski H, Bo ¨gel K, eds.Rabies in the tropics.
Berlin: Springer Verlag. pp 445–450.
35. Kitala PM, McDermott JJ, Kyule MN,
Gathuma JM (2000) Community-based active
surveillance for rabies in Machakos District,
Kenya. Prev Vet Med 44: 73–85.
36. Kuzmin IV, Niezgoda M, Franka R, Agwanda B,
Markotter W, et al. (2008) Lagos bat virus in
Kenya. J Clin Microbiol 46: 1451–1461. Available:
http://www.pubmedcentral.nih.gov/articlerender.
fcgi?tool=pubmed&pubmedid=18305130. Ac-
cessed 4 June 2009.
37. Fekadu M, Shaddock JH, Sanderlin DW,
Smith JS (1988) Efficacy of rabies vaccines
against Duvenhage virus isolated from European
house bats (Eptesicus serotinus), classic rabies and
rabies-related viruses. Vaccine 6: 533–539.
38. Hanlon CA, DeMattos CA, DeMattos CC,
Niezgoda M, Hooper DC, et al. (2001) Experi-
mental utility of rabies virus-neutralizing human
monoclonal antibodies in post-exposure prophy-
laxis. Vaccine 19: 3834–3842.
www.plosntds.org 8 July 2009 | Volume 3 | Issue 7 | e428